London rolls out additional evening and weekend GP appointments

London rolls out additional evening and weekend GP appointments

December 18 2017 London has become the first region to offer extended hours of services to all...

Scottish BMA meeting endorses new GP contract

Scottish BMA meeting endorses new GP contract

December 5 2017 GPs have voted in favour of the proposed new contract for general practice in...

NHS England to press ahead with curbs on prescribing items with little evidence base

NHS England to press ahead with curbs on prescribing items with little evidence base

December 1 2017 The first group of products that which should no longer be ordinarily prescribed...

New primary care guidance for commissioners issued

New primary care guidance for commissioners issued

November 21 2017 NHS England has issued new guidance for commissioners around primary care. The...

Burns review recommends how targets and health indicators should be developed in Scotland

Burns review recommends how targets and health indicators should be developed in Scotland

November 21 2017 A Scottish health review in Scotland has set out key principles and...

  • London rolls out additional evening and weekend GP appointments

    London rolls out additional evening and weekend GP appointments

    Monday, 18 December 2017 14:22
  • Scottish BMA meeting endorses new GP contract

    Scottish BMA meeting endorses new GP contract

    Tuesday, 05 December 2017 11:05
  • NHS England to press ahead with curbs on prescribing items with little evidence base

    NHS England to press ahead with curbs on prescribing items with little evidence base

    Friday, 01 December 2017 10:32
  • New primary care guidance for commissioners issued

    New primary care guidance for commissioners issued

    Tuesday, 21 November 2017 14:54
  • Burns review recommends how targets and health indicators should be developed in Scotland

    Burns review recommends how targets and health indicators should be developed in Scotland

    Tuesday, 21 November 2017 14:47

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Contract News

January 17 2018 Delays and issues with functionality in the electronic patient record are causing frustration, the Wales Audit Office has warned. It is also unclear whether intended benefits are...
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...